Treatment indentification with PARPi inhibitors

A complementary NGS diagnostic arrangement for therapies with PARPi inhibitors in BRCA1 / 2 and other types of cancer. Our integrated service that includes sample processing, sequencing, data analysis and reporting.

To identify cancer patients who may benefit from treatment with PARP inhibitors

The synthetic lethal interaction between PARP inhibition and homologous recombination repair deficiency (HRR) is being successfully exploited therapeutically in ovarian cancer, so three PARP inhibitors (olaparib, rucaparib and niraparib) have received approval of the United States Food and Drug Administration (FDA) as monotherapy. in patients with mutations in the germline or somatic BRCA1 / 2, or as maintenance therapy in recurrent platinum-sensitive disease, regardless of the status of the BRCA mutation. The FDA also approved olaparib for patients with HER2 negative metastatic breast cancer mutated in germline BRCA previously treated with chemotherapy. In addition, olaparib has received the designation of advanced therapy as a single agent for the treatment of metastatic prostate cancer resistant to castration, mutated, BRCA or ATM gene in patients who have received prior chemotherapy based on taxanes and at least one agent Hormone newer The selection of patients for therapy with PARP inhibitors is based on complementary diagnoses approved by the FDA, such as FoundationFocus CDxBRCA and BRACAnalysis CDx.

 

DIPIHIBITOR PARPi CDx is a complementary diagnostic arrangement based on next generation sequencing (NGS) for therapies with PARP inhibitors (PARPi) in several types of cancer. This arrangement is an integrated workflow from sample processing, sequencing, analysis to report generation.

Features

 

  • Rigorous validation: accuracy, reproducibility and stability have been validated with the Reference Standards and Horizon clinical samples.

 

  • Reliable interpretation of pathogenicity: Based on the ACMG / AMP guidelines and the internal database of the BRCA variant of DIPLOIDE, the ACMG pathogenicity interpretation channel guarantees the accuracy and reliability of the test results. It has been validated through the GenQA Classification of the BRCA Variant Test.

 

  • Short response time: 10 calendar days from the receipt of the sample to the delivery of the report

New diploide logo letters.png
0

EXPLORE

LEGAL

CONNECT WITH US

  • Black Facebook Icon
  • Black Twitter Icon
  • Black Instagram Icon
  • Black YouTube Icon

Facebook

Twitter

Instagram

YouTube

Linkedin

© 2019 by BIOMED DNA GROUP SAS